Rapport Therapeutics Inc (RAPP) Stock Analysis
Verdict: WATCH (do not buy)
Clinical success in RAP-219 is priced for perfection, but a massive cash runway protects against immediate solvency risks during trials.
Investment score: 58/100
Analysis as of
Is Rapport Therapeutics Inc stock worth reviewing? AI model thesis
RAPP is a high-conviction biotech play with unanimous analyst support but significant insider selling and zero revenue. Proper risk management is vital given the 2.52 Beta.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Rapport Therapeutics Inc opportunities and risks
What speaks for RAPP
- Strong Cash Runway
What speaks against RAPP
- Binary Clinical Trial Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RAPP | n/a | 77.2x | n/a | 96.3% | -536.4% | -5.2% |
| PBH | 12.6x | 2.2x | 10.1x | 54.0% | 17.5% | 10.8% |
| HRMY | 15.4x | 2.5x | 8.0x | 76.5% | 16.2% | 15.2% |
| OCUL | n/a | 43.0x | n/a | 87.2% | -558.2% | -10.8% |
| AMLX | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.9% |
| ANIP | 21.0x | 2.1x | 8.4x | 65.9% | 9.7% | 8.2% |
| Peer median | 12.6x | 2.2x | 8.0x | 65.9% | 9.7% | 8.2% |
Frequently asked questions about Rapport Therapeutics Inc (RAPP)
Is RAPP stock a good investment?
The cached TradeMates AI model rates Rapport Therapeutics Inc as WATCH (do not buy) with an investment score of 58/100. RAPP is a high-conviction biotech play with unanimous analyst support but significant insider selling and zero revenue. Proper risk management is vital given the 2.52 Beta. This is algorithmic model output, not personal investment advice.
Is RAPP stock a buy?
The TradeMates model verdict for RAPP is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.